Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-04 03:59:58 - browse：7

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： WHO recommends second malaria vaccine

WSS

After Sarepta trial failure, Duchenne families brace for more debate

Coloradans with cystic fibrosis could lose access to Trikafta

Lung cancer screening guidelines updated for cigarette smokers

Live blog: Hearing on CRISPR

How to convince healthy people to buy insurance

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

hotspot

Wikipedia

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

6 solutions to address cancer drug shortages and others

Malaria cases in Florida and Texas: Here’s what you need to know

Medicare proceeds with plan to claw back hospital funds

Drug repurposing or repositioning? The language matters

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Anesthesiologist group: stop taking Ozempic before surgery

Will an HIV vaccine ever be a reality?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

entertainment

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

WHO recommends second malaria vaccine

The health care issue Democrats can’t solve: hospital reform

Setback for rare diseases as Taysha Gene Therapies pulls back

CDC picks Alphabet's Verily for wasterwater surveillance contract

Gene therapy’s promise and the high cost of hope

Wikipedia

entertainment

hotspot

focus